News >

FDA Approves Iobenguane I-131 for Rare Neuroendocrine Tumors

Jason M. Broderick @jasoncology
Published: Monday, Jul 30, 2018

The FDA has approved iobenguane I-131 (Azedra) for adult and pediatric patients aged ≥12 years with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.

An expanded access program for iobenguane I-131 is currently available for patients with MIBG-avid malignant and/or recurrent PPGL. Outside of providing access to the medication, the program also plans to further assess safety (NCT02961491).
Jimenez C, Chin BB, Noto RB, et al. AZEDRA (iobenguane I 131) in patients with malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL): Final results of a multi-center, open-label, pivotal phase 2b study. Presented at: NANETS 2017 Symposium; October 19-21, 2017, Philadelphia, PA. Abstract C-28.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x